Premium Nahrungsergänzungsmittel | artgerecht

Exenatide – GLP-1 Agonist for Type 2 Diabetes

Exenatide is a blood sugar-lowering medication used to treat type 2 diabetes. It mimics the gut hormone GLP-1, stimulating insulin release in a glucose-dependent manner.

Regular tips about health Regular tips about health

Things worth knowing about "Exenatide"

Exenatide is a blood sugar-lowering medication used to treat type 2 diabetes. It mimics the gut hormone GLP-1, stimulating insulin release in a glucose-dependent manner.

What is Exenatide?

Exenatide is a synthetic drug belonging to the class of GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). It is used in the treatment of type 2 diabetes mellitus in adults when diet, exercise, and other antidiabetic medications are insufficient to achieve adequate blood glucose control. Exenatide is based on exendin-4, a naturally occurring peptide found in the saliva of the Gila monster (Heloderma suspectum).

Mechanism of Action

Exenatide mimics the action of the naturally occurring hormone GLP-1, which is released in the intestine after a meal. It binds to GLP-1 receptors in the pancreas and other tissues, producing the following effects:

Glucose-dependent insulin stimulation: Exenatide stimulates insulin secretion from beta cells only when blood glucose levels are elevated, resulting in a relatively low risk of hypoglycemia.
Suppression of glucagon secretion: It inhibits the inappropriate release of glucagon, a hormone that raises blood sugar levels.
Slowed gastric emptying: Food remains in the stomach longer, contributing to a prolonged feeling of fullness.
Appetite reduction: Through central effects in the brain, exenatide reduces hunger, which often leads to weight loss.

Indications

Exenatide is approved for the treatment of type 2 diabetes mellitus in adults who have not achieved adequate glycemic control with oral antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones. It can be used in combination with other medications or, depending on regulatory approval, as a monotherapy.

Forms and Dosage

Exenatide is available in two formulations:

Byetta® (short-acting): Administered as a subcutaneous injection twice daily, 60 minutes before the two main meals. The usual starting dose is 5 micrograms twice daily, which may be increased to 10 micrograms twice daily after 4 weeks.
Bydureon® (extended-release): Administered as a once-weekly subcutaneous injection at a fixed dose of 2 mg per week. This formulation provides stable drug levels throughout the week.

Side Effects

Like all medications, exenatide can cause side effects. The most common include:

Gastrointestinal complaints: Nausea, vomiting, diarrhea, and constipation – most common at the start of treatment and usually transient.
Hypoglycemia (low blood sugar): Particularly when used in combination with sulfonylureas or insulin.
Injection site reactions: Redness, swelling, or itching at the injection site.
Headache and dizziness.
Pancreatitis: A rare but serious side effect. Persistent abdominal pain should prompt immediate medical attention.

Contraindications and Precautions

Exenatide must not be used in:

Patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Patients with severe renal impairment (GFR below 30 ml/min).
Patients with known hypersensitivity to the active substance.

Caution is required in patients with a history of pancreatitis. Exenatide is not recommended during pregnancy or breastfeeding, as adequate safety data are not available for these populations.

Clinical Relevance and Benefits

Beyond blood glucose control, exenatide offers additional clinically relevant benefits. It frequently leads to weight loss of approximately 1–3 kg on average, which is particularly advantageous for overweight patients with type 2 diabetes. It also has a favorable effect on blood pressure. Unlike insulin, exenatide does not cause weight gain and is considered easier to manage in daily use.

References

European Medicines Agency (EMA): Summary of Product Characteristics for Bydureon and Byetta. Available at: www.ema.europa.eu
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006;368(9548):1696–1705.
American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S1–S321.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.